Immune-checkpoint inhibitors (ICIs), particularly inhibitors of PD-1/PD-L1, have been confirmed great benefits in treatment of NSCLC [24–27], but there is still a considerable proportion of patients with little efficacy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.